D.A. Davidson & CO. raised its holdings in CVS Health Corp (NYSE:CVS) by 3.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 582,998 shares of the pharmacy operator’s stock after acquiring an additional 18,368 shares during the quarter. CVS Health comprises 0.8% of D.A. Davidson & CO.’s portfolio, making the stock its 24th largest position. D.A. Davidson & CO. owned approximately 0.06% of CVS Health worth $45,894,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Camarda Financial Advisors LLC purchased a new position in CVS Health during the 2nd quarter valued at $102,000. Tdam USA Inc. raised its position in CVS Health by 59.6% in the 2nd quarter. Tdam USA Inc. now owns 28,548 shares of the pharmacy operator’s stock worth $1,837,000 after buying an additional 10,656 shares during the last quarter. Commonwealth Equity Services LLC raised its position in CVS Health by 21.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 452,306 shares of the pharmacy operator’s stock worth $29,106,000 after buying an additional 80,509 shares during the last quarter. CWM LLC raised its position in CVS Health by 96.3% in the 2nd quarter. CWM LLC now owns 2,821 shares of the pharmacy operator’s stock worth $182,000 after buying an additional 1,384 shares during the last quarter. Finally, Stoneridge Investment Partners LLC increased its position in shares of CVS Health by 8.7% during the 2nd quarter. Stoneridge Investment Partners LLC now owns 112,666 shares of the pharmacy operator’s stock valued at $7,250,000 after purchasing an additional 9,053 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.
Shares of NYSE CVS opened at $79.52 on Tuesday. CVS Health Corp has a 1 year low of $60.14 and a 1 year high of $83.88. The stock has a market cap of $81.71 billion, a PE ratio of 13.48, a price-to-earnings-growth ratio of 1.15 and a beta of 0.98. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.94 and a current ratio of 2.44.
In other CVS Health news, CFO David M. Denton sold 25,159 shares of the business’s stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total transaction of $2,015,990.67. Following the sale, the chief financial officer now directly owns 403 shares of the company’s stock, valued at approximately $32,292.39. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Lisa Bisaccia sold 21,534 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. Insiders sold 74,233 shares of company stock valued at $5,932,565 over the last 90 days. 0.53% of the stock is currently owned by insiders.
Several equities research analysts recently issued reports on CVS shares. Argus increased their target price on shares of CVS Health to $100.00 and gave the stock a “buy” rating in a report on Tuesday, November 13th. Loop Capital set a $80.00 price target on CVS Health and gave the stock a “hold” rating in a research report on Wednesday, November 28th. Evercore ISI initiated coverage on CVS Health in a research note on Wednesday, November 28th. They issued an “outperform” rating and a $89.00 target price on the stock. Goldman Sachs Group restated a “neutral” rating and set a $87.00 price target on shares of CVS Health in a research note on Thursday, November 29th. Finally, Cantor Fitzgerald started coverage on CVS Health in a research report on Sunday. They set an “overweight” rating and a $77.84 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $89.93.
TRADEMARK VIOLATION NOTICE: “D.A. Davidson & CO. Acquires 18,368 Shares of CVS Health Corp (CVS)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.com-unik.info/2018/12/04/d-a-davidson-co-acquires-18368-shares-of-cvs-health-corp-cvs.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Read More: Buyback For Investors Defined
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.